Literature DB >> 19151756

Regulation of non-AU-rich element containing c-fms proto-oncogene expression by HuR in breast cancer.

H-H Woo1, Y Zhou, X Yi, C L David, W Zheng, M Gilmore-Hebert, H M Kluger, E C Ulukus, T Baker, J B Stoffer, S K Chambers.   

Abstract

The role of RNA-binding proteins in cancer biology is recognized increasingly. The nucleocytoplasmic shuttling and AU-rich RNA-binding protein HuR stabilizes several cancer-related target mRNAs. The proto-oncogene c-fms, whose 3'untranslated region (3'UTR) is not AU-rich, is associated with poor prognosis in breast cancer. Using a large breast-cancer tissue array (N=670), we found nuclear HuR expression to be associated with nodal metastasis and independently with poor survival (P=0.03, RR 1.45), as well as to be co-expressed with c-fms in the breast tumors (P=0.0007). We described c-fms mRNA as a direct target of HuR in vivo, and that HuR bound specifically to a 69-nt region containing 'CUU' motifs in 3'UTR c-fms RNA. Overexpressing or silencing HuR significantly up- or down-regulated c-fms RNA expression, respectively. We also found that known glucocorticoid stimulation of c-fms RNA and protein is largely dependent on the presence of HuR. HuR, by binding to the 69-nt wild type, but not mutant, c-fms sequence can regulate reporter gene expression post-transcriptionally. We are the first to describe that HuR can regulate gene expression by binding non-AU-rich sequences in 3'UTR c-fms RNA. Collectively, our findings suggest that HuR plays a supportive role for c-fms in breast cancer progression by binding a 69-nt element in its 3'UTR, thus regulating its expression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19151756     DOI: 10.1038/onc.2008.469

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  20 in total

Review 1.  Posttranscriptional regulation of cancer traits by HuR.

Authors:  Kotb Abdelmohsen; Myriam Gorospe
Journal:  Wiley Interdiscip Rev RNA       Date:  2010-05-06       Impact factor: 9.957

2.  Posttranscriptional suppression of proto-oncogene c-fms expression by vigilin in breast cancer.

Authors:  Ho-Hyung Woo; Xiaofang Yi; Tiffany Lamb; Ina Menzl; Terri Baker; David J Shapiro; Setsuko K Chambers
Journal:  Mol Cell Biol       Date:  2010-10-25       Impact factor: 4.272

3.  Role of RNA binding protein HuR in ductal carcinoma in situ of the breast.

Authors:  Mira Heinonen; Annabrita Hemmes; Kaisa Salmenkivi; Kotb Abdelmohsen; Suvi-Tuuli Vilén; Marko Laakso; Marjut Leidenius; Tuula Salo; Sampsa Hautaniemi; Myriam Gorospe; Päivi Heikkilä; Caj Haglund; Ari Ristimäki
Journal:  J Pathol       Date:  2011-04-11       Impact factor: 7.996

4.  AngiotensinII induces HuR shuttling by post-transcriptional regulated CyclinD1 in human mesangial cells.

Authors:  Yu Che; Liu Yi; Javed Akhtar; Chen Bing; Zhang Ruiyu; Wan Qiang; Wang Rong
Journal:  Mol Biol Rep       Date:  2014-01-04       Impact factor: 2.316

5.  Musashi RNA-binding protein 2 regulates estrogen receptor 1 function in breast cancer.

Authors:  M-H Kang; K J Jeong; W Y Kim; H J Lee; G Gong; N Suh; B Győrffy; S Kim; S-Y Jeong; G B Mills; Y-Y Park
Journal:  Oncogene       Date:  2016-09-05       Impact factor: 9.867

6.  Potent synergistic effect of IL-3 and TNF on matrix metalloproteinase 9 generation by human eosinophils.

Authors:  Elizabeth A B Kelly; Lin Ying Liu; Stephane Esnault; Beatriz Helena Quinchia Johnson; Nizar N Jarjour
Journal:  Cytokine       Date:  2012-02-09       Impact factor: 3.861

Review 7.  Role of CSF-1 in progression of epithelial ovarian cancer.

Authors:  Setsuko K Chambers
Journal:  Future Oncol       Date:  2009-11       Impact factor: 3.404

8.  Autocrine inhibition of the c-fms proto-oncogene reduces breast cancer bone metastasis assessed with in vivo dual-modality imaging.

Authors:  Justin J Jeffery; Katie Lux; John S Vogel; Wynetta D Herrera; Stephen Greco; Ho-Hyung Woo; Nisreen AbuShahin; Mark D Pagel; Setsuko K Chambers
Journal:  Exp Biol Med (Maywood)       Date:  2014-03-05

Review 9.  HuR function in disease.

Authors:  Subramanya Srikantan; Myriam Gorospe
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01

10.  Regulation of closely juxtaposed proto-oncogene c-fms and HMGXB3 gene expression by mRNA 3' end polymorphism in breast cancer cells.

Authors:  Ho-Hyung Woo; Setsuko K Chambers
Journal:  RNA       Date:  2021-06-21       Impact factor: 5.636

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.